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response (PR) or stable disease (SD)) and local tumor control. 
Indices of SUVmax in tumors/SUVmean in muscle were 
calculated for individual patients. Normalized SUV FDG 
(SUVmax tumor/SUV mean muscle) was plotted against 
normalized baseline SUV F-MISO1 (SUVmax tumor/SUV mean 
muscle) and the correlation was calculated. Follow-up 
included MRI every 3 months. 
Results: Patients undergoing definitive RCTx for SCCHN 
(n=16) were included. Tumor hypoxia was present in >90% of 
patients at baseline whereas at subsequent examinations 
hypoxia was sharply diminished in incidence (36% and 27%) 
and extent. On quantitative analysis the mean SUVmax 
indices decreased from 1.9 (week 0) to 1.6 (week 2) and 1.3 
(week 5). No correlation was found for normalized SUV FDG 
and the corresponding normalized baseline SUV F-MISO1 
(Pearson correlation coefficient 0.32). MRI scans obtained at 
treatment week 5 showed CR in 8 %, PR in 77 % and SD in 15 
% of patients. Kaplan-Meier analysis of local recurrence 
against time after treatment for a mean follow up of 39 
months showed significantly worse local tumor control for 
tumors hypoxic on F-MISO PET 1 and 2 (p<0.05) compared to 
non-hypoxic-tumors. 
Conclusions: Stable reduction of tumor hypoxia was found in 
the majority of patients. A significant correlation between 
tumor hypoxia obtained by F-MISO PET (F-MISO 1, 2) and local 
control was found.  
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Purpose/Objective: Radiotherapy (RT) for non-small cell lung 
cancer (NSCLC) may cause late toxicities, such as heart 
toxicity, changes in pulmonary function (PF) and lung 
fibrosis, but late toxicity data are scarce in the literature for 
this category of patients. The objective of this study was to 
analyze long term PF changes after definitive RT for patients 
with NSCLC. PF was measured by FEV1 and FVC as assessed by 
spirometry.  
Materials and Methods: This is a single institution study of 
patients receiving definitive RT for NSCLC between 1996 and 
2010. A total of 556 consecutive treated patients with 3063 
pairs of pulmonary function test (PFTs) were screened for 
eligibility for inclusion in the analysis of late changes in PF. 
To be eligible, patients had at least 3 PFTs after baseline. In 
this study, baseline was defined as 12 months after RT 
commencement to overcome a possible effect of tumor 
shrinkage and the acute side effect, radiation induced 
pneumonitis. PFT within 6 months prior to thoracic 
progression were excluded. The final study group comprised 
106 patients with 1286 pairs of PFTs. For each patient 
complete dosimetric data, including GTV, PTV, mean lung 
dose, Vx for total lung volume were available as well as 
patient specific pretreatment factors such as age, gender, 
smoking status, performance status, and pretreatment PF. 
Multivariable regression analyses were performed with 
patient, treatment, and dose-volume metrics as covariates to 
investigate their possible impact on long term PF. FEV1 and 
FVC were analyzed separately. 
Results: The long-term change in PF relative to the 1-year 
baseline was estimated by linear regression. Relative to the 
1-year-FEV1 most patients experienced a decrease in FEV1 
over time. The change in FEV1 per year, varied considerably 
among patients (Fig 1). Treatment year and V60 were the only 
covariates having a significant impact on FEV1 deterioration. 
Patients treated early in the period experienced a larger 
functional decline. Also for FVC a linear relationship with the 
follow-up time was found, again with large inter-patient 
variation. An unsuspected finding was that high V60 was 
associated with less decline in FVC, but FVC may be a less 
reliable parameter for pulmonary damage. 
 
Figure 1. Data on pulmonary function expressed in FEV1 from 
2 patients.The straight lines are the estimated loss, λ in the 
model. Zero denotes baseline, i.e. 12 months after start of 
radiotherapy. 
Conclusions: Patients experience a decline in FEV1 after the 
12-month value following definitive RT for NSCLC. In a 
multivariable analysis, deterioration of FEV1 was significantly 
associated with V60 of the lung (risk factor) and treatment 
year (risk factor). Early calendar year of treatment was 
associated with higher risk of deterioration. The yearly 
decline in FVC was less than in FEV1. A large V60 was, 
somewhat puzzling, associated with a lower FVC decline in a 
multivariable analysis. 
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Purpose/Objective: The state of oligometastases was divided 
into sync-oligometastases and oligo-recurrence, the 
